Toggle navigation
Home
Medical
Lilly Calls It Quits on Baricitinib's Development for Lupus
1-2-2022
Medical
https://www.medscape.com/cx/rssfeeds/2700.xml
64
The company said it is stopping phase 3 trials because of disappointing results. Medscape Medical News
Share
Tweet
+1
Read The Rest
at : https://www.medscape.com/cx/rssfeeds/2700.xml
Related News
In Small Study, CAR-T Therapy Pushes Lupus Into Remission
Single-cell transcriptomics of immune cells in lymph...
Research reveals pivotal role of C/EBPb in the...
Open letter calls for further sugar reduction programmes
Pathway uncovered for greatest lupus genetic risk factor,...
Scientists unravel the development of main immune cell...
Gum Health Day 2022 calls for prevention, early...
STAT+: With new diabetes drug data, Eli Lilly is taking...
Antibiotic found to prevent autism development in mice,...
YAP1 molecule essential to development of gastruloids...